PRMEPrime Medicine, Inc.

$771M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$205M

Net Income

-$198M

EPS (Diluted)

$-2.18

Cash Flow

Operating Cash Flow

-$165M

Free Cash Flow

-$174M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$194M

Total Liabilities

$61M

Stockholders' Equity

$133M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$205M	-$117M	-75.7%
Net Income	-$198M	-$122M	-62.6%

PRME FY 2023 Earnings — Prime Medicine, Inc. Revenue & Financial Results | Market Cap Arena